Aska Of Japan, Actavis Of Iceland To Form Generics Venture
This article was originally published in PharmAsia News
Executive Summary
Japan's Aska Pharmaceutical and Iceland's Actavis Group plan a joint venture next year to develop and market generic drugs. The deal, expected to take effect next April in Japan, would give Aska a 55 percent stake and Actavis the rest. Under the plan, Aska would draw on Actavis-produced raw materials to produce drugs in Japanese facilities, with expectations their first co-developed drugs would reach the market in 2010. Actavis has a pipeline of about 1,000 drugs, but the joint venture expects to produce only about seven a year. (Click here for more - a subscription may be required
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.